Abstract. The function of FAM9C encoding a testis-exclusively expressed and nuclear-localized protein remains unknown. In the present study, we evaluated the role of FAM9C in human hepatocellular carcinoma. We found that among three FAM9 family members, only FAM9C was frequently upregulated in HCC specimens compared with that in corresponding adjacent non-cancer liver tissues. FAM9C was located in the nucleus of HCC cells, as shown by both western blotting and immumofluorescence assays. Significantly, FAM9C overexpression promoted proliferation, clonogenicity in an anchorage-dependent manner, in vivo tumorigenicity of YY-8103, and Huh-7 cells. In contrast, FAM9C knockdown suppressed proliferation, anchorage-dependent colony formation and in vivo tumorigenicity of QGY-7703, and BEL-7404 cells. However, FAM9C had no significant effects on cell cycle progression when FAM9C was stably overexpressed in Huh-7 cells or knocked down in BEL-7404 cells. Most importantly, FAM9C regulated activation of Akt and UV-induced apoptosis in HCC cells. FAM9C overexpression increased the phosphorylation levels of Akt and anti-apoptotic ability of Huh-7 cells, whereas endogenous FAM9C knockdown reduced the phosphorylated levels of Akt and anti-apoptotic ability of BEL-7404 cells. Furthermore, the anti-apoptotic function of FAM9C could be prevented when the PI3K-Akt pathway was in a loss-offunction caused by RNA interference against Akt or PI3K inhibitor LY294002 in HCC cells. Taken together, our data demonstrate that FAM9C as a novel cancer testis gene plays an anti-apoptotic role in human hepatocellular carcinoma through activating the PI3K/Akt signaling pathway, and serves as a promising target for HCC therapy.
Introduction
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy with the continually increasing incidence, and the second major cause of cancer-related deaths worldwide (1, 2) . In China, the most common cause of this neoplasm is the chronic infection induced by the hepatitis B virus. Other important etiological factor are cirrhosis, chronic viral hepatitis (hepatitis C virus), alcohol abuse, obesity, hemochromatosis, α1-antitripsin deficiency and toxins similar to aflatoxin (3) . Because recent development of genomic technologies has empowered survey of molecular aberrations and deregulations directly from patient specimens in a comprehensive way, some presented prognostic/predictive targets for HCC biomarkers improved the prognosis of patients by guiding treatment decision and allocation of medical resources (4) (5) (6) . Cancer/testis genes are normally expressed by gametes and trophoblasts, as well as aberrantly expressed in a range of malignant tumors of unrelated histological origin, including the liver. CT genes are a class of closely cancer-related biomarkers. Since germline stem cells and their trophoblastic derivatives share many characteristics with tumour cells, the activation of portions of the germline gene-expression in cancer cells could contribute to the malignant phenotype, including proliferation, survival, invasiveness, immune evasion and metastatic capacity (7) .
A number of CT genes have been found expressed in HCC and their products are promising targets for antigen-specific immunotherapy of this tumor. For example, the mRNA expressions of MAGE1, SSX-1, CTp11 and HCA587, were detectable in diverse percentage of HCC samples examined (8, 9) . The brother of the regulator of imprinted sites (BORIS) as a novel member of the CT antigens may be an auxiliary diagnosis index and a novel favorable prognostic indicator of HCC (10) . However, whether their recurrent expression contributes to tumorigenesis, is still under investigation. Recent studies demonstrate the important role of CT genes in malignant features of HCC cells. A known member of CT antigens family, NY-ESO-1, whose expression is associated with worse HCC outcome, increases tumor cell migration (11) . To identify novel CT genes, some genes with testisexclusive expression have been searched for through published literature. In the present study, we paid attention to a reported gene family, which included three members with testis-exclusively expression, FAM9A, FAM9B and FAM9C (12) and investigated their expression profiles in human hepatocellular carcinoma (HCC). Interestingly, among the three members, only FMA9C was frequently upregulated in HCC specimens compared with that of the corresponding non-cancerous livers. Nevertheless, the physiological and the pathological function of FAM9C is not understood. Therefore, we further evaluated the role of FAM9C in HCC cells. Significantly, the resulting data demonstrated that FAM9C overexpression promoted proliferation, colony-forming growth and in vivo tumorigenicity of HCC cells, and RNA interference against FAM9C suppressed these phenotypes in HCC cells. We found that FAM9C endowed HCC cells with resistance to apoptosis through PI3K-Akt pathway. Our results reveal that upregulated FAM9C as a novel cancer testis gene plays an anti-apoptotic role in human HCC.
Materials and methods
Tissue specimens and cell lines. HCC specimens used in the present study were obtained from HCC patients who underwent liver resection and gave their informed consent. The following liver tumor-derived cell lines SSMC-7721, QGY-7703, BEL-7404, BEL-7405, YY-8103 and Huh-7, were employed in the present study. These cell lines were grown in Dulbecco's modified Eagle's medium (DMEM), supplemented with heatinactivated 10% fetal bovine serum (Gibco, Carlsbad, CA, USA) at 37˚C in a 5% CO 2 humidified incubator.
Antibodies and reagents. Antibodies against FAM9C, GAPDH, Lamin A and β-actin were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Antibodies against phospho-Akt (pAkt and Ser473) and Akt were from Cell Signaling Technology (Beverly, MA, USA). Propidium iodide (PI), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 5-Aza-2'-deoxycytidine (5-Aza-dC), 4'-6-diamidino-2-phenylindole (DAPI) and PI3K inhibitor LY294002 were purchased from Sigma Chemical Co. (St. Louis, MO, USA). ) normalized by β-actin expression (13) .
5-Aza-2'-deoxycytidine (5-

Immunohistochemistry and immunofluorescence assay.
Formalin-fixed HCC samples were paraffin-embedded and cut into 4-µm sections. The sections were deparaffinized and dehydrated, and then treated with methanol containing 0.3% H 2 O 2 to inhibit endogenous peroxidase. The slides were incubated with anti-FAM9C goat polyclonal antibody (Santa Cruz Biotechnology) at 37˚C for 2 h and then at 4˚C overnight, followed by incubation with a horseradish peroxidase-conjugated anti-goat antibody (Dako Japan Ltd., Kyoto, Japan) at 37˚C for 1 h. The signals were detected using Diaminobenzidine Substrate kit (Vector Laboratories, Burlingame, CA, USA). Counterstaining was performed with hematoxylin. In addition, the slides with HCC specimens and the corresponding adjacent non-HCC livers were simultaneously used in the immunohistochemistry staining, and were then assessed by visual inspection and the estimation of the percentage of immunopositive cells. Immunofluorescence assay was performed to detect endogenous FAM9C in BEL-7404 cells. These cells were plated on polylysine-treated slides and then incubated at 37˚C for 1 h. The fixed cells were blocked with phosphate-buffered saline buffer containing 5% bovine serum albumin and then stained with anti-FAM9C antibody (Santa Cruz Biotechnology) at 4˚C overnight, followed by incubation with fluorescein isothiocyanate-conjugated goat anti-IgG antibody (Gibco-BRL, Grand Island, NY, USA) at 4˚C for 2 h. After rinsing, the slides were analyzed using immunofluorescence microscopy.
RNA interference (RNAi).
Small interference RNAs (siRNAs) targeting FAM9C, Akt and negative control siRNA (si-NC) were chemically synthesized (Invitrogen-Life Technologies). Two siRNAs against FAM9C with high efficiency were used in the functional experiment assays, and their sequences were as follows: FAM9C-si1, sense, 5'-GGACCAGUUGGAGGUU CAAdTdT-3', antisense, 5'-UUGAACCUCCAACUGGUCC dTdT-3'; FAM9C-si2, sense, 5'-CCAAGGAGCUAGAAGAU AUdTdT-3', antisense, 5'-AUAUCUUCUAGCUCCUUGT dT-3'; si-NC, sense, 5'-UUCUCCGAACGUGUCACGUdT dT-3', antisense, 5'-ACGUGACACGUUCGGAGAAdTdT-3'. As well, the sequences of a siRNA against Akt were as follows:
Construction of recombinant plasmids. The full-length FAM9C ORF (501 bp, GenBank accession number NM_174901.4) was amplified by RT-PCR from BEL-7404 cells cDNA. The primers for FAM9C ORF were as follows: forward, 5'-TCAGAATTCATGGCTGCCAAGGACCAGT TGGAGG-3'; reverse, 5'-TCAGGTACCTCAATCTCTTTCA GTTCCTTTCCCA-3'. The PCR product was then inserted into pcDNATM3.1B (Invitrogen) through EcoRI-and KpnIadapter. In addition, synthesized DNA nucleotide fragments of short hairpin RNA (shRNA) for knocking down endogenous FAM9C, was inserted into pSUPER (Oligoengine; Seattle, WA, USA). The sequences of these synthesized oligonucleotides for FAM9C silencing were as follows: Cell growth curve. HCC cells with FAM9C overexpression or knockdown were seeded in triplicate into 96-well plates (3,000 cells/well) respectively and then incubated with 5 mg/ml (10 µl) MTT for 4 h at 37˚C, then the medium was replaced with 100 µl dimethylsulfoxide (DMSO) for 10 min every 24-h intervals for 5-6 days. Cell growth curves were generated by calculating the mean value of the optical density measurements at 492 nm using a microplate reader. All experiments were independently repeated at least 3 times.
Colony formation assay. FAM9C was overexpressed in HCC cell lines Huh-7 and YY-8103 through the transfection with recombinant pcDNA3.1-FAM9C plasmid, additionally endogenous FAM9C was knocked down in QGY-7703, BEL-7404 cells via pSUPER-shFAM9C plasmids. Transfected cells were cultured on 100-mm dishes for colony formation, followed by the addition of G418 (Life Technologies) to the medium at a final concentration of 0.6-1 mg/ml. After 3-4 weeks, the remaining colonies were washed twice with PBS and counted on crystal violet-stained dishes. All experiments for observing colony formation were independently repeated at least three times.
Establishment of stable cell lines.
To establish a stably FAM9C-expressing HCC cell line, HuH-7 cells were transfected with the recombinant plasmid pcDNA3.1B-FMA9C, then cultured by G418 (Life Technologies). An immunoblot assay was employed to examine the expression of FAM9C in nine individual colonies. One colony with steady and strong FAM9C expression was selected as study object, and another colony without ectopic FAM9C expression was used as mock object. In addition, BEL-7404 cell line with stable FAM9C knockdown was also established by transfection with plasmid pSUPER-FAM9C-sh2, with the methods mentioned above. A colony of BEL-7404 cells transfected with plasmid pSUPERshNC containing irrelevant sequence was used as a negative control.
Western blot assay. Cultured HCC cells were harvested with trypsin-EDTA and then centrifuged at 500 x g for 5 min. Cytoplasmic and nuclear proteins were extracted using NE-PER ® Nuclear and Cytoplasmic Extraction reagents (Thermo Scientific Pierce), according to the manufacturer's instructions. Protein extracts were separated by 12% SDS-PAGE and transferred onto Hybond-C nitrocellulose membranes (Amersham Life Science, Buckinghamshire, UK). After blocking with PBS containing 5% non-fat milk, the membrane was incubated for immunoblot analysis with primary antibodies, followed by incubation with an IRDye 800DX-conjugated, affinity-purified secondary antibody. Signals were detected using the Odyssey Infrared Imaging system (LI-COR Biosciences).
Flow cytometric analysis.
Flow cytometry was used to analyze cell cycle and cell apoptosis. For DNA content analysis, cells were fixed in 70% ethanol, rehydrated in PBS, and treated for 30 min with RNase A (10 mg/ml) and for 5 min with propidium iodide (10 µg/ml). For UV-induced apoptosis analysis, 3J/cm 2 , 5 min UV-irradiated cells (1x10 6 cells) were harvested and washed twice with cold PBS. Then, Annexin V-FITC staining was performed according to the protocol provided by the manufacturer (BD Biosciences Pharmingen, San Diego, CA, USA). Briefly, cells were resuspended in binding buffer at a concentration of 1x10 6 cells/ml, and 5 µl of Annexin-FITC and 100 µl cell suspension (1x10 5 cells) were gently mixed and incubated for 15 min at room temperature in the dark. Cells were analyzed for apoptosis by flow cytometry on a FACSCalibur (Becton-Dickinson, Mountain View, CA, USA).
Tumorigenicity assay in nude mice. A total of 2x10 6 offspring Huh-7 cells stably expressing ectopic FAM9C were subcutaneously injected into the flank of nude mice, and the same amount of progeny Huh-7 cells without ectopic FAM9C expression as mock control were injected into the opposite flank of the same mice. Cells (2x10 6 ) derived from BEL-7404 with stable knockdown of endogenous FAM9C were injected subcutaneously into the flank of nude mice, and the same amount of BEL-7404 cells from the colony transfected with pSUPER-shNC were injected into the opposite flank of the same mice. Tumor growth kinetics was estimated by measuring tumor size and volume every 3-4 days. Tumor volume was determined using the following formula: 1/2 x width 2 x length.
Statistical analysis. Statistical analysis was performed by the Student's t-test using SSPS software (SPSS, Inc., Chicago, IL, USA). P-value <0.05 was considered to indicate a statistically significant result.
Results
FAM9C was frequently upregulated in human HCC.
To evaluate the role of FAM9 members in HCC, we first investigated the transcriptional levels of three FAM9 family members, FAM9A, FAM9B and FAM9C, in 22 pairs of human HCC specimens by semi-quantitative and real-time RT-PCR. The data showed that only FAM9C mRNA was obviously elevated in more than a half of HCC specimens examined, as compared with that of corresponding non-cancerous livers, while FAM9A mRNA was not specifically amplified and FAM9B exhibited disordered expression in these specimens (Fig. 1A and B) . To confirm this result, FAM9C was further evaluated in additional 46 paired human HCC specimens by semi-quantitative and real-time PCR. The result showed the relative mRNA level of FAM9C was significantly upregulated in HCC tumor specimens compared with corresponding adjacent non-tumor livers (P<0.001) (Fig. 1C) , and the upregulation of FAM9C mRNA was obvious in 25 of the 46 HCC specimens as shown by semi-quantitative PCR (Fig. 1D) . Furthermore, we also examined the expression and location of FAM9C protein in a pair of HCC specimens using immunohistochemical staining with a specific antibody against FAM9C. The resulting data showed that FAM9C protein was located in the nuclei, and presented more expression in tumor tissue than adjacent nontumor sample (Fig. 1E) . Collectively, these data demonstrated that FAM9C was frequently elevated in human HCCs and as a novel cancer testis gene.
The expression and subcellular location of FAM9C in HCC cell lines.
The expression pattern of FAM9C was further evaluated in some HCC cell lines by RT-PCR. The result showed that FAM9C presented relatively high expression in QGY-7703 and BEL-7404 cells but low or no expression in other cell lines examined ( Fig. 2A) . To investigate whether DNA methylation regulates the FAM9C expression in HCC cells, we treated two HCC cell lines SSMC-7721 and BEL-7405 with 5-Aza-dC, a demethylating agent. RT-PCR analysis showed that FAM9C expression was upregulated in these treated cells as compared with untreated controls (Fig. 2B ). In addition, we determined the expression and subcellular location of FAM9C protein in HCC cells by a western blot assay of cytoplasmic and nuclear extracts, as well as a subcellular immunofluorescence assay. In conformity with the mRNA expression levels of FAM9C, FAM9C protein exhibited also relatively high expression in nuclear extracts of QGY-7703 and BEL-7404 cells, but without expression in cytoplasmic extracts of these cell lines (Fig. 2C) . FAM9C was located in the nucleus in BEL-7404 cells, as indicated by immunofluorescence assay (Fig. 2D) .
FAM9C overexpression promotes growth and colony formation of HCC cells in vitro.
To evaluate the role of FAM9C on HCC cells, recombinant pcDNA3.1-FAM9C was transiently transfected into Huh-7 and YY-8103 cells with little FAM9C expression. The result showed that overexpressed FAM9C, as demonstrated by western blot assay, significantly promoted cell growth of the two HCC cell lines compared with those transfected with empty vector (Fig. 3A and B) . Furthermore, FAM9C also promoted the anchorage-dependent colony formation of Huh-7 and YY-8103 cells (Fig. 3C and D) . These data suggest that FAM9C overexpression plays an important role in promoting HCC cell growth, colony formation in vitro.
FAM9C knockdown inhibits cell proliferation and colony formation of HCC cells in vitro.
To further investigate the effect of FAM9C on HCC cell proliferation and colony formation, we used chemically synthesized siRNAs and shRNAs derived from recombinant pSUPER to knock down endogenous FAM9C in BEL-7404 and QGY-7703 cells. Through evaluating the knockdown efficiency of four siRNAs against FAM9C (data not shown), the two efficient siRNAs (FAM9C-si1 and FAM9C-si2) were used to silence endogenous FAM9C in BEL-7404 and QGY-7703 cells (Fig. 4A) . The growth curve results showed that FAM9C knockdown significantly inhibited the proliferation of BEL-7404 and QGY-7703 cells (Fig. 4B) . Moreover, pSUPER vectors carrying shRNAs (FAM9C-sh1 and FAM9C-sh2) against FAM9C were employed to FAM9C knockdown, where endogenous FAM9C was silenced in the above two HCC cell lines respectively, as demonstrated by western blot assay (Fig. 4C) . The colony formation assay demonstrated that FAM9C knockdown significantly suppressed the anchorage-dependent clonogenicity of BEL-7404 and QGY-7703 cells (Fig. 4D) . These collective data implied that endogenous FAM9C could be essential for maintaining the proliferation and anchorage-dependent colony formation of HCC cells in vitro.
The effect of FAM9C on the tumorigenicity of HCC cells in nude mice. To determine whether the dysregulated FAM9C contributes to hepatocarcinogenesis in vivo, Huh-7 cells (2x10 6 ) stably expressing FAM9C were subcutaneously injected into a flank of athymic nude mice, and the same amount of subcloned Huh-7 cells transfected with pcDNA3.1-FAM9C but without ectopic FAM9C expression as Mock control were subcutaneously injected into the other flank of the same nude mice. As expected, the stably FAM9C-expressing Huh-7 cells formed tumors faster than the mock cells without FAM9C expression under the observation for four weeks (P<0.05) (Fig. 5A) . The removed xenograft tumors from nude mice demonstrated that FAM9C overexpression significantly promoted the tumor size and weight as compared with that of mock objects (P<0.05) (Fig. 5B and C). These data indicated that FAM9C overexpression significantly promoted tumorigenicity in vivo of Huh-7 cells. Moreover, a total of 2x10 6 BEL-7404 cells, whose endogenous FAM9C was stably knocked down by plasmid pSUPER-FAM9C-sh2, were subcutaneously injected into a flank of athymic nude mice, and the same amount of cells transfected with control plasmid (pSUPER-shNC) as negative control was injected into the opposite flank of the same mice. Notably, FAM9C knockdown led to significant tumor growth retardation under observation for four weeks (P<0.01) (Fig. 5D) , where BEL-7404 cells with FAM9C silence had low tumorigenicity in vivo in four of six mice tested, whereas cells used as controls formed tumors in all six mice (Fig. 5E) . The removed xenograft tumors from nude mice showed that FAM9C silence significantly restrained the tumor size and weight as compared with that of controls (P<0.01) (Fig. 5F ). The result indicated that silencing of FAM9C significantly inhibited tumorigenicity in vivo of BEL-7404 cells.
FAM9C plays an anti-apoptotic role through activating the PI3K-Akt signaling pathway in HCC cells.
To explore the molecular mechanisms by which FAM9C contributes to HCC cell proliferation, clonogenicity in vitro and tumorigenicity in vivo, we first analyzed the cell cycle of HCC cells with FAM9C overexpression or knockdown. However, FAM9C overexpression and knockdown did not alter cell cycle distribution of Huh-7 and BEL-7404 cells respectively (Fig. 6A  and B) . As reported, FAM9C protein exhibited similarity to SYCP3, a component of the synaptonemal complex (12) . More importantly, SYCP3 led to activation of Akt, resulting in the upregulation of anti-apoptotic proteins (14) . To determine whether FAM9C as a homologous gene of SYCP3 activates Akt signaling pathway, we examined the activity of Akt pathway by western blot assay while FAM9C overexpression or knockdown in HCC cells. We found that the phosphorylation levels of Akt significantly increased in Huh-7 cells expressing FAM9C, whereas the phosphorylation levels of Akt obviously decreased in BEL-7404 cells with FAM9C knockdown (Fig. 6C) . These data indicated that FAM9C regulated activation of Akt.
To further address the role of FAM9C-induced activation of Akt in HCC cells, we investigated cell apoptosis of UV-irradiated HCC cells with FAM9C overexpression or knockdown by flow cytometry method. The resulting data demonstrated that FAM9C overexpression significantly reduced the proportion of apoptotic Huh-7 cells (P<0.01), while FAM9C knockdown significantly increased the apoptotic percentage of BEL-7404 cells (P<0.01), indicating that FAM9C endowed HCC cells with resistance to apoptosis ( Fig. 6D and E) . In addition, to determine whether the activation of PI3K-Akt pathway is directly responsible for the anti-apoptotic role of FAM9C in HCC cells, we further performed cell apoptosis assays when Akt was silenced by a validated siRNA (data not shown) or blocked by LY294002, a known inhibitor of PI3K-Akt signaling pathway. Interestingly, the results demonstrated that both siRNA against Akt and LY294002 inhibitor significantly abolished or even prevented the anti-apoptotic effect of FAM9C in Huh-7 and BEL-7404 cells with UV exposure (P<0.01) (Fig. 6D and F) . Thus, these collective data suggest that FAM9C plays the anti-apoptotic role through mediating PI3K-Akt signaling pathway in HCC cells.
Discussion
FAM9 gene family mapped to Xp22.33-p22.31 includes three members, FAM9A, FAM9B and FAM9C, which are expressed exclusively in testis (12) and have potential as cancer testis genes. In the present study, we first investigated their expression profiling of the three FAM9 family members in human HCC specimens. Notably, only FAM9C was frequently elevated in HCC specimens, suggesting that FAM9C could be a novel cancer testis gene. FAM9C expression was reactivated in HCC cells treated with the demethylating agent 5-aza-2'-deoxycitidine, implying that promoter demethylation was related to FAM9C deregulation in HCC. Although global DNA hypomethylation as a characteristic biomarker of liver cancer (15) has been identified as a cause of oncogenesis (16) , some specific mechanisms especially the involvement in reactivated cancer testis genes are still obscure.
The crucial question is whether FAM9C upregulation contributes to neoplastic phenotype of HCC. As previously reported, restricted tissue-specific expression of FAM9C to testis, subcellular localization of the encoded protein to nucleus, and homology to SYCP3, encoding an essential structural component of the synaptonemal complex which is involved in synapsis, recombination and segregation of meiotic chromosomes, indicate FAM9C protein may be involved in the meiotic process (12) . SYCP3 has been reported to be aberrantly expressed in tumors (17) (18) (19) . SYCP3 impairs mitotic recombination by interfering with BRCA2, highlighting a new mechanism for chromosomal instability in cancers (20) . However, the function of FAM9C gene is not yet determined by experiments. In the present study, FAM9C overexpression promoted cell proliferation, in vitro anchorage-dependent colony formation and in vivo tumorigenicity of Huh-7 cells. On the contrary, FAM9C knockdown induced by RNA interference inhibited cell proliferation, in vitro clonogenicity and in vivo tumorigenicity of BEL-7404 cells. These data showed that FAM9C as a novel cancer testis gene contributed to HCC and thereby could be a potential therapeutic target for HCC. However, further cell cycle analysis by flow cytometry showed FAM9C had no significant effect on cell cycle progression. Thus, whether FAM9C is involved in the formation of the synaptonemal complex or DNA replication are worthy further attention.
The molecular mechanism involved in these effects of FAM9C on HCC cells in vitro and in vivo, indicated that FAM9C was able to regulate the activation of Akt signaling pathway. PI3K/Akt/mTOR signaling pathway is commonly deregulated in a variety of cancers due to genetic alternations and promotes cellular growth, proliferation, and survival (21-24). Therefore, PI3K/Akt/mTOR signaling pathway represents a suitable and promising therapeutic target in HCC, and many targeted agents against this signaling pathway are in clinical trials (25) (26) (27) (28) . In the present study, we revealed that upregulated FAM9C resulted in activation of Akt in HCC cells, implying that mutually targeting the FAM9C and PI3K/Akt/mTOR pathway may promote inhibitory effects on tumors. We have noted that the demethylating reagent, 5-Aza-2'-deoxycytidine (5-Aza-dC) exerted antitumor effect on HCC cells (29) , but also caused the upregulation of FAM9C in HCC cells. In light of the FAM9C-promoting effects through the activation of Akt, we deduce that the combination of 5-Aza-dC and inhibitors of PI3K-Akt signaling pathway (e.g., LY294002) would more effectively inhibit proliferation of HCC cells. In conclusion, our findings demonstrated that FAM9C as a novel cancer testis gene played an anti-apoptotic role through regulating PI3K-Akt signaling pathway in human hepatocellular carcinoma. We propose that FAM9C represents a novel target for enhancing the response of HCC cells to demethylating reagents.
